We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
Read MoreHide Full Article
Anavex Life Sciences Corp. (AVXL - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) considers its pipeline candidate, oral blarcamesine, eligible for a centralized regulatory review in the EU.
This indicates that Anavex may file a single marketing application to the European Medicines Agency. The company initiated the regulatory submission of blarcamesine for the treatment of Alzheimer’s disease to the EMA in November 2023.
The marketing authorization application, upon potential approval, will grant the company direct access to the European Union market. Anavex is planning to submit a marketing authorization application for blarcamesine at the earliest possible date in 2024.
Shares of the Anavex were up 13.2% on Dec 19 following the announcement of the news. The stock has rallied 15.6% in the past year against the industry’s decline of 19.6%.
Image Source: Zacks Investment Research
Per the company, blarcamesine is being evaluated in a IIb/III clinical study for Alzheimer's disease. Besides showing significant improvement in dementia symptoms in the study, treatment with blarcamesine also led to a reduction in pathological aggregation of amyloid in early Alzheimer’s disease and reduced brain volume loss, a renowned marker of neurodegeneration.
Anavex’s orally administered blarcamesine is an easier-to-use formulation. The oral treatment does not require complex logistics resources and added personnel for drug administration and monitoring for brain edema and brain bleeds.
Anavex is also evaluating blarcamesine in several other central nervous system indications. The candidate is being developed in mid-to-late-stage studies for treating Rett syndrome, Parkinson's disease, schizophrenia, Fragile X and other rare diseases.
In the past 60 days, estimates for Journey Medical’s 2023 loss per share have narrowed from $1.28 to 16 cents. Meanwhile, loss per share estimates for 2024 have narrowed from 41 cents to 35 cents. In the past year, shares of DERM have surged 568.4%.
Earnings of Journey Medical beat estimates in one of the last four quarters while missing the same on the remaining three occasions. DERM delivered a four-quarter earnings surprise of 118.25%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2023 loss per share have narrowed from $2.07 to 9 cents. Meanwhile, loss per share estimates for 2024 have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 11.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 72 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 64 cents. In the past year, shares of PBYI have lost 19.8%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
Anavex Life Sciences Corp. (AVXL - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) considers its pipeline candidate, oral blarcamesine, eligible for a centralized regulatory review in the EU.
This indicates that Anavex may file a single marketing application to the European Medicines Agency. The company initiated the regulatory submission of blarcamesine for the treatment of Alzheimer’s disease to the EMA in November 2023.
The marketing authorization application, upon potential approval, will grant the company direct access to the European Union market. Anavex is planning to submit a marketing authorization application for blarcamesine at the earliest possible date in 2024.
Shares of the Anavex were up 13.2% on Dec 19 following the announcement of the news. The stock has rallied 15.6% in the past year against the industry’s decline of 19.6%.
Per the company, blarcamesine is being evaluated in a IIb/III clinical study for Alzheimer's disease. Besides showing significant improvement in dementia symptoms in the study, treatment with blarcamesine also led to a reduction in pathological aggregation of amyloid in early Alzheimer’s disease and reduced brain volume loss, a renowned marker of neurodegeneration.
Anavex’s orally administered blarcamesine is an easier-to-use formulation. The oral treatment does not require complex logistics resources and added personnel for drug administration and monitoring for brain edema and brain bleeds.
Anavex is also evaluating blarcamesine in several other central nervous system indications. The candidate is being developed in mid-to-late-stage studies for treating Rett syndrome, Parkinson's disease, schizophrenia, Fragile X and other rare diseases.
Zacks Rank & Other Stocks to Consider
Anavex currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the healthcare sector are Journey Medical Corporation (DERM - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Journey Medical’s 2023 loss per share have narrowed from $1.28 to 16 cents. Meanwhile, loss per share estimates for 2024 have narrowed from 41 cents to 35 cents. In the past year, shares of DERM have surged 568.4%.
Earnings of Journey Medical beat estimates in one of the last four quarters while missing the same on the remaining three occasions. DERM delivered a four-quarter earnings surprise of 118.25%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2023 loss per share have narrowed from $2.07 to 9 cents. Meanwhile, loss per share estimates for 2024 have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 11.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 72 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 64 cents. In the past year, shares of PBYI have lost 19.8%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.